Thyroid Cancer, Papillary
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2029.
Clinical MilestonesViewHide
- 2025-11-24ClinicalDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Results expected Q4 2029
- 2025-09-08ClinicalA Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid CancersResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Thyroid Cancer, Papillary2
- Thyroid Neoplasms2
- Tumor Microenvironment2
- Chemokine CXCL131
- Disease Progression1
- Immunotherapy1
- Machine Learning1
- Thyroid Carcinoma, Anaplastic1
Leading journals4
- Frontiers in immunology1
- JAMA oncology1
- JCI insight1
- Nature communications1
Leading researchers8
- Wang Y2
- Al Ghuzlan A1
- Alves VA1
- Asa SL1
- Baloch ZW1
- Barletta JA1
- Basolo F1
- Chang C1
Affiliations (unnormalised)6
- Fudan University Shanghai Cancer Center2
- Brigham and Women's Hospital1
- Department of Clinical Oncology1
- Department of Pathology and Laboratory Medicine1
- Fudan University1
- Fudan University Science Park1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
An ADENOCARCINOMA that originates from follicular cells of the THYROID GLAND and accounts for the majority of THYROID CANCER cases. Cells exhibit enlarged, oval, or elongated morphologies with clear, round, nuclei. Fusions of RET, NTRK1, TPM3, and PCM1 genes are associated with this cancer.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.